Objectives: To establish the effect of continuous renal replacement therapy on outcome in pediatric acute liver failure. Design: Retrospective cohort study. Setting: Sixteen-bed PICU in a university-affiliated tertiary care hospital and specialist liver centre. Patients: All children (0-18 yr) admitted to PICU with pediatric acute liver failure between January 2003 and December 2013. Interventions: Children with pediatric acute liver failure were managed according to a set protocol. The guidelines for continuous renal replacement therapy in pediatric acute liver failure were changed in 2011 following preliminary results to indicate the earlier use of continuous renal replacement therapy for both renal dysfunction and detoxification. Measurements and Main Results: Of 165 children admitted with pediatric acute liver failure, 136 met the inclusion criteria and 45 of these received continuous renal replacement therapy prior to transplantation or recovery. Of the children managed with continuous renal replacement therapy, 26 (58%) survived: 19 were successfully bridged to liver transplantation and 7 spontaneously recovered. Cox proportional hazards regression model clearly showed reducing hyperammonemia by 48 hours after initiating continuous renal replacement therapy significantly improved survival (HR, 1.04; 95% CI, 1.013-1.073; p = 0.004). On average, for every 10% decrease in ammonia from baseline at 48 hours, the likelihood of survival increased by 50%. Time to initiate continuous renal replacement therapy from PICU admission was lower in survivors compared to nonsurvivors (HR, 0.96; 95% CI, 0.916-1.007; p = 0.095). Change in practice to initiate early and high-dose continuous renal replacement therapy led to increased survival with maximum effect being visible in the first 14 days (HR, 3; 95% CI, 1.0-10.3; p = 0.063). Among children with pediatric acute liver failure who did not receive a liver transplant, use of continuous renal replacement therapy significantly improved survival (HR, 4; 95% CI,; p = 0.006). Conclusion: Continuous renal replacement therapy can be used successfully in critically ill children with pediatric acute liver failure to provide stability and bridge to transplantation. Inability to reduce ammonia by 48 hours confers poor prognosis. Continuous renal replacement therapy should be considered at an early stage to help prevent further deterioration and buy time for potential spontaneous recovery or bridge to liver transplantation. (Crit Care Med 2016; 44:1910-1919 
children will recover and in how much time, and which ones will rapidly deteriorate, remains an enigma for intensivists (2) . In the wake of organ scarcity on one hand and subjecting children to unnecessary transplantation with risks of surgery and life-long immunosuppression on the other, the role of supportive therapies to stabilize a child to help facilitate these decisions is an area of growing importance (3) (4) (5) .
One of the most significant achievements in intensive care medicine in the last 40 years has been the development of continuous renal replacement therapy (CRRT) (6) . CRRT is now the mainstay treatment for managing acute kidney injury (AKI) in PICUs and has significantly reduced mortality (7) (8) (9) . AKI is a common multifactorial complication of PALF that occurs in approximately 55% of all cases (10) (11) (12) . Renal dysfunction pretransplant determines the degree of renal dysfunction posttransplant. Therefore, tackling AKI pretransplant should improve the condition of the patient posttransplant. In these patients, CRRT has also been shown to successfully reduce ammonia (13) , reduce lactate (14, 15) , and optimize fluid balance (16) . However, all of these observations have been reported in adult patients. Recent research on critically ill children with PALF has demonstrated that high ammonia (17, 18) , high lactate (19) , and fluid overload (20) are associated with increased mortality. In addition to the risk of AKI in PALF, hyperammonemia contributes to the development of cerebral edema, and there is a strong risk of fluid overload especially after fluid resuscitation due to the systemic inflammatory response syndrome. This raises the question whether the use of CRRT should be extended to nonrenal indications in patients with PALF, as a detoxification mechanism.
Despite its rapidly increasing uptake, evidence to evaluate whether CRRT is of justifiable benefit in these situations is currently lacking (21) , and there are no agreed guidelines on when or what dose it should be initiated in PALF. This study aimed to describe our experience on the use of CRRT in PALF from over a decade of data.
MATERIALS AND METHODS

Study Population
King's College Hospital is a supra-regional centre for liver referrals in the United Kingdom and operates one of the largest liver transplantation programs in Europe. All children admitted to the PICU at King's College Hospital that met the criteria for PALF from January 2003 to December 2013 were entered into the PALF registry. PALF was defined according to the criteria used by the PALF Study Group (22) : "1) No evidence of preexisting chronic liver disease; 2) Biochemical evidence of acute liver injury (elevation in aspartate aminotransferase/alanine aminotransferase) within 8 weeks of the onset of symptoms; 3) Hepatic-based coagulopathy (prothrombin time [PT] > 15 or international normalized ratio [INR] > 1.5 in the presence of hepatic encephalopathy [HE] or PT > 20 or INR > 2 in the absence of HE) within 8 weeks of the onset of symptoms." Children with PALF admitted to the PICU for only posttransplant care were excluded. Children who were commenced on CRRT prior to transplantation or recovery were included in the CRRT treatment group (Fig. 1) . Factors affecting survival in children with PALF treated with CRRT were studied. Due to preliminary findings, the guideline for CRRT in PALF was changed in 2011; therefore the clinical outcomes in these two eras, pre-and post-2011, have been compared.
Data Collection
Medical records, laboratory data, and observation charts were reviewed for all patients in the PALF registry. Patient characteristics including age, gender, height, weight, details and duration of presenting symptoms and signs, time to first medical contact, time to PICU transfer, and prereferral care were also recorded. Etiology of PALF was classified into seven categories: indeterminate, toxic, infectious, metabolic, ischemic, infiltrative, and autoimmune.
For clinical observations and laboratory data, admission and peak values within the first 24 hours were recorded from the unit's Clinical Information System. Pediatric Logistic Organ Dysfunction (PELOD) score and Pediatric Index of Mortality (PIM) 2 were calculated for each patient (23) . Timing of listing for liver transplantation and indication along with transplant date, type, and details of any postoperative complications and the date that the child was removed from the list due to spontaneous recovery or clinical deterioration were included. Duration of PICU stay, survival on hospital discharge, and survival at 6 months postdischarge were also recorded.
For children commenced on CRRT, time from PICU admission to initiation of CRRT, indication, duration, and markers of disease progression at 0, 24, and 48 hours after starting CRRT including arterial ammonia, lactate, mean arterial blood pressure, percentage fluid overload, and creatinine were recorded. Indications for CRRT were classified into the following eight categories: oligo-anuria, hyperkalemia greater than 5.5 mmol/L, fluid overload greater than 10%, hyperammonemia greater than 200 μmol/L, hepatic encephalopathy grade greater than 2, hyponatremia less than 130 mEq/L, lactate greater than 2 μmol/L not responding to fluid therapy, or metabolic acidosis pH less than 7.1 resistant to fluid therapy. Importantly, not one single indication was considered a sole reason to initiate CRRT; it was a clinical decision and all contributory factors were recorded. The daily percentage fluid overload prior to and post initiation of CRRT was calculated using the formula by Goldstein et al (24) .
Any complications secondary to CRRT including catheter malfunction, anticoagulation problems, bleeding, thrombosis, infection, or shock were also recorded.
CRRT
The duty consultant pediatric intensivist determined the requirement for CRRT. CRRT was commenced according to a local protocol with predilution to achieve required ammonia and lactate clearances and electrolyte and fluid homeostasis ( Table 1 ). All children had ultrasound-guided venous access via a high flow double lumen catheter ("Vascath"; Gambro, Stockholm, Sweden) placed either in the internal jugular, subclavian, or the femoral vein. The sizes of the double lumen venous access catheters used were predefined according to body weight-6.5F (14%), 8F (28%), 10F (15%), 11.5F (32%), and 13.5F (11%). Children with less than 10 kg were filtered using HF03, 10-50 kg using HF07, and greater than 50 kg using HF1200 (membrane surface area: HF03 = 0.3 m 2 , HF07 = 0.7 m 2 , and HF1200 = 1.2 m 2 ). All the filters were made of polyethersulfone fiber. Predilution was incorporated in all filtration episodes using "Accusol 35," a lactate-free electrolyte solution. The net delivered dose varied and on an average was 8.2 ± 1.1 mL/kg/hr less than the prescribed dose.
The machine used for CRRT was "Aquarius" (Nikkiso Europe GmbH, Hannover, Germany). Details of CRRT recorded included vascath size and location, anticoagulation dose, filter life, dose of CRRT, and complications. Blood flow rates ranged from 50 to 250 mL/min depending on age (Table 1) . Predilution continuous venovenous hemofiltration was the most commonly used modality. Anticoagulation used was prostacyclin (2-6 ng/ kg/min) if the activated clotting time (ACT) was 160-220 seconds and low-dose heparin if the ACT was less than 160 seconds unless contraindicated. If ACT is more than 220 seconds, no anticoagulation was used. To facilitate toxin removal, CRRT dose was sequentially increased to a maximum of 100 mL/kg/hr.
Statistical Analysis
Statistical data were analyzed with STATA software version 14 (StataCorp, College Station, TX). Continuous data were expressed as the mean ± sd and categorical data as the actual count with percentages unless stated otherwise. The primary outcome of this study was survival up to 60 days after the PICU admission with or without liver transplantation: 1) death awaiting transplantation, 2) death after transplantation, 3) alive with native liver, and 4) alive with transplanted organ. Secondary outcome measures included the trend in markers for disease progression after initiating CRRT. The data were analyzed to see what, if any, variables at admission were associated with mortality and to identify prognostic markers in children with PALF on CRRT. Univariate analysis was performed to compare variables between survivors and nonsurvivors at hospital discharge using the unpaired t test for continuous data and Fisher exact test for categorical data. For analyzing trends in markers of disease progression, regression lines and box plots were used and compared by primary outcome. Analysis of variance (ANOVA) and covariance was used to compare disease severity markers at 0, 24, and 48 hours after initiation of CRRT. Kaplan-Meier curves and Cox model were used to look at survival of children up to 60 days after admission. Data were adjusted for severity of illness using the PELOD scoring system. A p value of less than 0.05 was considered statistically significant.
Ethics
Since it was a retrospective analysis of already collected routine data, ethical approval was not deemed necessary.
RESULTS
Baseline Characteristics
From January 2003 to December 2013, 136 patients with PALF met the inclusion criteria of being managed on the unit prior to transplantation or recovery. Forty-five of these children received CRRT as part of their management (Fig. 1) . A comparison between patient demographics and selected physiologic and laboratory values on admission to PICU are shown in Supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/B878). Among the patients who underwent CRRT, the common etiology was indeterminant (53%) followed by metabolic (20%) and toxic (13%).
Baseline characteristics between survivors and nonsurvivors treated with CRRT were compared ( Table 2) . Nonsurvivors were significantly younger (p = 0.017) and weighed less (p = 0.006). They also spent on average 10 days more on the ward prior to PICU transfer (p = 0.051). Toxic (p = 0.024) or metabolic (p = 0.015) etiology was associated with higher mortality. Peak arterial ammonia in the first 24 hours of admission were also significantly higher among nonsurvivors (p = 0.025). All children who died on CRRT were ventilated and on inotropes.
Anticoagulation and Complications in CRRT
A total of 198 filters were utilized between the 45 patients receiving CRRT for PALF. Prostacyclin was used in 72% of these filters, unfractionated heparin in 18% filters, and no anticoagulant in 10%. Median filter life was 59 hours (44.7-60.2) using prostacyclin, 27 hours (21.1-33.7) using heparin, and 20 hours (14.6-25.3) using no anticoagulation. Safety and efficacy of prostacyclin as an anticoagulant was acceptable with 1.9 bleeding episodes per 1,000 hours of CRRT and hypotension requiring fluids or vasopressors occurring in less than 10% of filter episodes. The site of venous access (femoral vs internal jugular) did not contribute to circuit life among this subgroup. There was one episode of hemopneumothorax with internal jugular venous catheter insertion and three episodes of vascular access rewiring due to thrombus; overall the procedure was well tolerated. 
Timing of Initiation and Indications for CRRT
The median time to initiate CRRT from PICU admission was 27 ± 6.9 hours and one in three were started on CRRT within the first 8 hours of admission to the unit. Median time to initiate CRRT in survivors was lower compared to nonsurvivors (15.8 ± 3.0 vs 32.4 ± 6.9 hr; p = 0.023). Thirty patients (66.7%) had multiple indications for starting CRRT. The most common indications were oligo-anuria (n = 14; 31%), hyperammonemia (n = 13; 29%), hepatic encephalopathy (n = 12; 27%), high lactate (n = 10; 22%), fluid overload (n = 6,;13%), resistant metabolic acidosis (n = 3; 7%), resistant hyperkalemia (n = 1; 2%), and hyponatremia (n = 1; 2%). The mean duration of CRRT was 54 hours.
Effect on Outcome
Overall survival of patients with ALF on CRRT at discharge was 58% (Fig. 2) . A significant increase in mortality was seen in children who were less than 1-year old (heart rate [HR], 6; 95% CI, 2.0-18.2; p = 0.001; Fig. 3) . Severity was adjusted for by the PELOD score as opposed to the PIM2 score as it does not accurately reflect outcomes in PALF (25) . Twenty-six of the 45 patients were bridged successfully to either native organ recovery (n = 7) or successful liver transplantation (n = 19). In total, 24 patients requiring CRRT underwent a liver transplant and 79% of these survived. Of the 21 who did not, only one third spontaneously recovered. As liver transplantation interferes with the natural progression of disease, we looked at the effect of CRRT only in those children with PALF who did not undergo transplantation, that is, either had spontaneous regeneration of native liver or died without a transplant-those who received CRRT had a significantly increased chance of survival (HR, 4; 95% CI, 1.5-11.6; p = 0.006; Fig. 4) .
Cox proportional hazards regression model adjusting for severity of illness (PELOD), ammonia at presentation, ability of CRRT to decrease ammonia by 48 hours, and time to initiate CRRT from PICU admission clearly shows that in spite of high ammonia levels in both survivors and nonsurvivors at initiation of CRRT, a decrease in ammonia by 48 hours of starting CRRT significantly improved survival (HR, 1.04; 95% CI, 1.013-1.073; p = 0.004). On average, for every 10% decrease in ammonia from baseline at 48 hours, the likelihood of survival increased by 50%. Time to initiate CRRT from PICU admission was also found to be lower in survivors compared to nonsurvivors, although statistical significance is borderline (HR, 0.96; 95% CI, 0.916-1.007; p = 0.095). For every 1 hour delay in initiating CRRT, likelihood of mortality increased by 4%. 
Efficacy of CRRT
To review the efficacy of CRRT in PALF, daily markers of disease progression including arterial ammonia, lactate, percentage fluid overload, creatinine, and mean arterial pressure were reviewed using ANOVA at 0, 24, and 48 hours after initiation of CRRT ( Table 3) . There was a significant reduction in ammonia (p = 0.001) and lactate (p = 0.043) within 48 hours of initiating CRRT among survivors. Although the mean level of creatinine and percentage fluid overload also decreased, the difference was not statistically significant. Figure 5 is a box plot analysis of the trend in ammonia over time by mortality. This clearly demonstrates that although ammonia is high at initiation of CRRT in both survivors and nonsurvivors, in survivors the ammonia is significantly lower after 48 hours of CRRT, whereas in nonsurvivors levels remained high (p ≤ 0.001). As demonstrated by multivariate analysis, inability of ammonia to be removed even after 48 hours of CRRT is a poor prognostic sign (p = 0.004).
Although not a controlled variable change, survival in PALF increased by 9% from 65% before the change in guidelines in 2011. Figure 6 shows the trend in survival pre and post guideline change. The most significant difference was seen in the first 14 days (HR, 3; 95% CI, 1.0-10.3; p = 0.063).
DISCUSSION
Despite the increasing use of CRRT in children with acute liver failure (ALF), there is a paucity of data surrounding its effect on outcome and applicability as a detoxification mechanism. The present study examined an 11-year institutional experience from the PICU at a specialist liver unit to evaluate whether the use of CRRT in these critically ill children is of justifiable benefit.
Of note, when the prospective pediatric CRRT registry was split into survival rates according to the diagnoses that led to the use of CRRT, children with liver disease had the lowest survival at 31% compared to the 58% average for all other diagnoses (26) . In this study, almost all children who required CRRT also required inotropes (91%) and ventilation (100%). This suggests that the children who went on to require CRRT in PALF were much more unstable during their admission and highlights just how sick these children are. As such, it would be misrepresentative to compare outcomes of the treatment and nontreatment group. Likewise, it would be unethical to withhold CRRT from a critically ill child due to its proven success in AKI, a common complication of PALF, and anecdotal and theoretical evidence for detoxification in PALF for the purpose of a randomized controlled trial. As such evidence will need to be sought through observational studies to establish the effect on outcome.
This study found that children frequently had more than one indication for CRRT prior to commencing therapy. Traditionally, CRRT has been used to manage renal dysfunction, which is a common complication of PALF. It is important not to forget that AKI is often multifactorial in PALF with hypovolemia being the most common precipitating factor setting the stage for acute tubular necrosis (27) . Although renal impairment was the indication for CRRT in a significant number of patients included in this study (oligo-anuria, 31%; fluid overload, 13%; and resistant hyperkalemia, 2%), more frequently CRRT is being used regardless of the presence or absence of renal dysfunction as a detoxification mechanism. The potential for recovery of native organ function coupled with the insufficient donor organ supply and risk of death or deterioration awaiting a compatible transplant, has focused attention on using detoxification mechanisms as liver support devices until recovery from PALF or bridging to transplantation. As such, initiating CRRT in PALF now serves a dual purpose: 1) for managing the AKI and fluid imbalances, which frequently complicate cases and 2) as a detoxification mechanism for the high ammonia, lactate, and metabolic disturbances which set in.
In this study, two of the indications for initiating CRRT were hyperammonemia greater than 200 µmol/L or hepatic encephalopathy greater than grade 2, which was present in a quarter of children (29% and 27%, respectively). It is well established that when ammonia is not metabolized by the failing liver, it is detoxified to glutamine in the brain, which is osmotically active and this is now thought to be responsible for astrocyte swelling and cytotoxic edema seen in PALF (28) (29) (30) (31) . Among survivors, CRRT was successful in reducing arterial ammonia (p ≤ 0.001). Interestingly, there was a much greater mortality among children whose level of arterial ammonia rose between the value at admission to PICU to the value at initiation of CRRT. This suggests that the intensivist should not wait, but intervene early at the first sign of rising hyperammonemia. Ability to reduce ammonia after 48 hours of starting CRRT was the most significant factor for survival on multivariate analysis (p = 0.004). This is important as in rapidly progressive PALF, the first 24-48 hours are vital to create a good milieu to facilitate spontaneous regeneration or prevent deterioration while awaiting for a suitable donor organ to become available. It remains to be seen whether this could be used as a marker of prognosis to help guide decisions regarding transplantation or prioritization of scarce donor organs.
Other significant risk factors for mortality in children with PALF treated with CRRT at admission included age (p = 0.017), weight (p = 0.006), time on ward prior to PICU transfer (p = 0.051), serum lactate (p = 0.003), INR (p = 0.062), peak levels of arterial ammonia in the first 24 hours (p = 0.009), and PALF with toxic and metabolic etiology. Age less than 1 year lends a significantly worse prognosis to this group of patients (Fig. 3) due to their smaller size, rapidly progressive etiologies, and increased waiting time for liver transplantation. This implies in the case of rapidly progressive PALF, early transfer to specialist liver transplant centers is critical especially in younger children with raised ammonia or INR greater than 4 of toxic or metabolic etiology as mortality is significantly higher.
In order to see whether CRRT can alter the natural progression of PALF, those patients with PALF who did not undergo transplantation and only received medical interventions were analyzed. The survival without transplant was much higher among the children who received CRRT versus those who did not (Fig. 4) . CRRT in these patients optimizes overall milieu including fluid balance and removal of toxic products to facilitate spontaneous recovery.
Due to reports of increased survival in using CRRT as a detoxification mechanism and earlier initiation in adult patients with ALF, and preliminary findings at our PICU, the PICU guidelines on the indications for CRRT in PALF were changed in 2011. In addition to signs of renal dysfunction, CRRT was initiated for hepatic encephalopathy (grade > 2) or hyperammonemia (NH 3 > 150 µmol/L and not getting controlled, or an absolute value > 200 µmol/L) along with metabolic abnormalities including hyponatremia. Higher doses of CRRT were also introduced, starting at 60 mL/kg/hr and increasing to 100 mL/kg/hr if toxin removal was inadequate, and bigger-sized vascaths appropriate to all age groups were introduced to ensure adequate circuit life and CRRT dose delivery. The effect of these changes is seen predominantly in the first 14 days, which is the time critical period to ensure that the child is in a stable condition either for spontaneous regeneration or liver transplantation.
Despite its increasing uptake, clear-cut consensus is lacking surrounding optimal CRRT delivery including time of initiation and dose. There is a growing body of evidence from adults with AKI that earlier initiation of CRRT has a significant beneficial impact on survival (32, 33) . This study likewise found that delays in initiation of treatment are associated with higher mortality and suggests that the intensivist should intervene at an early stage to have the best chance of survival. Regarding optimal doses, Davenport et al (34) showed improved cardiovascular stability in ALF using high filtration rates in particular where severe lactic acidosis was present or vasopressors were required, which applied to 93% of the children with PALF on CRRT in our group. In pediatrics, recent reports from France and Tokyo have demonstrated improved beneficial effects in children with PALF undergoing high volume hemofiltration (35, 36) . As such at King's College Hospital, CRRT is started early in the course of PALF patients who are intubated and ventilated for grade greater than 2 encephalopathy with high arterial ammonia levels, using hemofiltration as the preferred modality. The dose is then increased as required to achieve effective ammonia clearance due to the increased risk of mortality without a delta fall as highlighted in this study.
Another area of controversy is the use of anticoagulation. Despite the prolongation of routine coagulation tests in ALF, Habib et al (37) highlighted the need for anticoagulation due to the procoagulant state. Anticoagulation is therefore used in nearly all children with PALF undergoing CRRT in this study, with prostacyclin being the most frequently used anticoagulant. No complications related to anticoagulant use were observed. In addition to beneficial effects of prostacyclin as an anticoagulant, it can help to optimize oxygen delivery and uptake in critically ill patients, which can help improve ultimate prognosis (38) .
This study validates the acceptable safety and efficacy of prostacyclin as an anticoagulant in CRRT for PALF. Some centers have started using citrate despite initial fears of citrate accumulation as it is now shown that this can be predicted by the Ca total-to-Ca ionic ratio. Though this ratio can rise, equalization of initial metabolic acidosis is possible without major disturbances of acid-base and electrolyte status with acceptable filter lives (39) . This study has its limitations. First, this is a single centre experience with a relatively small sample size. It is extremely difficult to compare outcomes between CRRT and non-CRRT groups despite controlling for the severity of illness especially when the etiology is diverse. Ideally a propensity score should be used, which controls for the characteristics leading to the decision to use CRRT; however, it was not feasible due to the sample size and variability in characteristics of patients treated with CRRT versus those without. Therefore, it is difficult to make conclusions that outcomes are related to the treatment effect of CRRT only, although there are significant associations, these must be further tested. However, due to the rarity and severity of PALF, we feel the results are of value for guiding best practice.
CONCLUSIONS
When decisions regarding risks of surgery and prioritization of donor organs are critical, such as in rapidly progressing PALF, the importance of stabilizing a child to help facilitate these decisions is fundamental to survival. This study demonstrates that early, intensive CRRT can be used successfully in PALF for managing both AKI and toxin accumulation to provide an environment conducive to regeneration or to prolong the window of opportunity for successful liver transplantation. Furthermore, if patients are to undergo transplantation, they are presented in a more stable condition especially with regards to fluid homeostasis that can significantly reduce mortality in this frequently fatal condition.
